Cancer News and Research

Latest Cancer News and Research

Scientists discover important new biomarker that could improve HER2 targeted cancer treatments

Scientists from the School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin have made a significant discovery of a new biomarker which may help overcome resistance to newer and more targeted anti-cancer drugs, such as Herceptin, for HER2 positive cancers. These findings may also help the early identification of patients who will benefit more from these treatments.

11 Jun 2014

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO).

11 Jun 2014

UCF College of Nursing interim dean receives NIH grant to improve care for critically-ill patients

More than one hospital television drama has played out an emergency room scene where a patient has to be "tubed" to re-establish breathing.

11 Jun 2014

EU-funded project aims to identify potential new targets for cancer therapy

Targeted therapies have revolutionised the treatment of cancer since they were first introduced. Amongst the first medications approved in Europe, was the breast cancer drug Herceptin, which was approved in 2000. Then, the drug Glivec, was initially introduced to treat a certain form of leukaemia, and approved in 2001. Targeted therapies specifically inhibit molecules within so-called signalling pathways that usually control cell growth, death and differentiation. If they are altered, for example falsely inactivated or activated, the cells may start growing in an uncontrolled manner.

11 Jun 2014

Instant oatmeal provides greater satiety than equal calories of ready-to-eat oat cereal

New research published in the Nutrition Journal reveals that calorie-for-calorie, even a serving of instant oatmeal is more filling than a ready-to-eat (RTE), oat-based cereal.

11 Jun 2014

New framework for monitoring oral cancer development, progression, recurrence

Each year, approximately 22,000 Americans are diagnosed with oral cancer. The five-year survival rate of 40% in the U.S. is one of the lowest of the major cancers, and it has not improved in the past 40 years.

11 Jun 2014

Researchers discover strong genetic risk factor for type 2 diabetes in Latin American patients

In the largest study of its kind published to date, an international team of researchers in Mexico and the United States has discovered a strong genetic risk factor for type 2 diabetes that primarily affects Latin American patients, but is rare elsewhere.

11 Jun 2014

New guidelines aim to improve delivery of prostate cancer survivorship care

New American Cancer Society Prostate Cancer Survivorship Care guidelines released today outline posttreatment clinical follow-up care for the myriad of long-term and late effects an estimated 2.8 million prostate cancer survivors in the United States may face.

11 Jun 2014

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.

11 Jun 2014

VuCOMP receives FDA approval for M-Vu CAD for mammography version 3.1

VuCOMP, Inc., leading developer of advanced computer vision systems for the detection of breast cancer, announced today that it has received U.S. Food and Drug Administration approval for M-Vu CAD for mammography version 3.1. Concurrently, VuCOMP is releasing an update to its CAD station which includes the ability to process additional standard screening views.

10 Jun 2014

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany.

10 Jun 2014

$arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM$

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study of the Company's lead candidate, ARGX-110, in patients with refractory Waldenström's macroglobulinemia (WM).

10 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer.

10 Jun 2014

Findings add surprising new dimension to understanding of antibody repertoires

As elite soldiers of the body's immune response, B cells serve as a vast standing army ready to recognize and destroy invading antigens, including infections and cancer cells. To do so, each new B cell comes equipped with its own highly specialized weapon, a unique antibody protein that selectively binds to specific parts of the antigen.

10 Jun 2014

Wistar findings suggest means of boosting initial immune response

Your first response to an infectious agent or antigen ordinarily takes about a week, and is relatively weak. However, if your immune system encounters that antigen a second time, the so-called memory response is rapid, powerful, and very effective.

10 Jun 2014

Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized-but some cases simply do not respond to this treatment.

10 Jun 2014

Researchers reveal mysterious behavior of individual cells using radioluminescence microscopy

With a new molecular imaging system powerful enough to peer down to 20-micrometer resolution, researchers can now use radioluminescence to examine the characteristics of single, unconnected cells. The result is a fascinating picture of diversity among cells previously assumed to behave the same, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

10 Jun 2014

MD Anderson study shows that needle biopsy underused in breast cancer patients

Needle biopsy, the standard of care radiological procedure for diagnosing breast cancer, is underused with too many patients undergoing the more invasive, excisional biopsy to detect their disease, according to research from The University of Texas MD Anderson Cancer Center.

10 Jun 2014

Children who undergo complex imaging tests may have increased risk of cancer

Children with heart disease are exposed to low levels of radiation during X-rays, which do not significantly raise their lifetime cancer risk.

10 Jun 2014

Cancer News and Research

Latest Cancer News and Research

Scientists discover important new biomarker that could improve HER2 targeted cancer treatments

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

UCF College of Nursing interim dean receives NIH grant to improve care for critically-ill patients

EU-funded project aims to identify potential new targets for cancer therapy

Instant oatmeal provides greater satiety than equal calories of ready-to-eat oat cereal

New framework for monitoring oral cancer development, progression, recurrence

Researchers discover strong genetic risk factor for type 2 diabetes in Latin American patients

New guidelines aim to improve delivery of prostate cancer survivorship care

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

VuCOMP receives FDA approval for M-Vu CAD for mammography version 3.1

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

Celsion signs definitive asset purchase agreement to acquire EGEN

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Findings add surprising new dimension to understanding of antibody repertoires

Wistar findings suggest means of boosting initial immune response

Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Researchers reveal mysterious behavior of individual cells using radioluminescence microscopy

MD Anderson study shows that needle biopsy underused in breast cancer patients

Children who undergo complex imaging tests may have increased risk of cancer

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in